Centre Testing International Group (300012) Q4 2025 earnings summary

Executive summary

• Revenue reached ¥6.62 billion in 2025, up 8.82% year-over-year; net profit attributable to shareholders was ¥1.02 billion, up 10.35% year-over-year.

• Operating cash flow increased 29.02% year-over-year to ¥1.37 billion, reflecting improved cash collection and business quality.

• The company continued its global expansion through strategic acquisitions in Africa, Europe, and Southeast Asia, strengthening its international presence.

• R&D investment rose 9.71% to ¥581 million, representing 8.77% of revenue, supporting innovation and digital transformation.

• The board proposed a cash dividend of ¥1.5 per 10 shares for 2025.

Financial highlights

• EBITDA for 2025 was ¥1.68 billion, up 8.97% year-over-year.

• Gross margin was 48.62%, slightly down 0.85 percentage points from the previous year.

• Net assets attributable to shareholders increased 10.99% to ¥7.67 billion.

• Basic and diluted EPS were both ¥0.6075, up 10.45% year-over-year.

• Non-recurring gains totaled ¥66 million, mainly from government grants and investment returns.

Outlook and guidance

• The company will continue to focus on high-quality growth, digital transformation, and international expansion.

• Strategic priorities include strengthening core business, expanding in emerging sectors (AI, robotics, low-altitude economy), and enhancing ESG capabilities.

• R&D investment will remain at 8–10% of revenue to drive innovation.

• The company aims to further improve operational efficiency and cash flow management.